You are here: Industry Insights > RRMS

News List

SMC approves funding for four new medicines on the NHS pharmatimes
February 09, 2021
In its February 2021 meeting, the Scottish Medicines Consortium (SMC) has accepted four new medicines for use by the NHS in Scotland.
NICE no for BMS’ multiple sclerosis drug Zeposia pharmatimes
January 25, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has rejected Bristol Myers Squibb’s (BMS) Zeposia (ozanimod) for the treatment of relapsing/remitting multiple sclerosis (RRMS).
Bristol Myers Squibb receives EC approval for Zeposia in adults with RRMS with active disease pharmaceutical-business-review
June 01, 2020
Bristol Myers Squibb announced that the European Commission (EC) has approved Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.
Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians worldpharmanews
May 08, 2019
Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians.
Ocrelizumab reccommended for relapsing remitting multiple sclerosis europeanpharmaceuticalreview
April 16, 2019
Ocrelizumab has been recommended by the Scottish Medicines Consortium to treat relapsing remitting multiple sclerosis (RRMS) in adults...
FDA approves Novartis’ oral multiple sclerosis drug Mayzent pharmaceutical-technology
April 11, 2019
Novartis has obtained approval from the US Food and Drug Administration (FDA) for its relapsing multiple sclerosis (RMS) drug Mayzent (siponimod)...
Banner Receives FDA Tentative Approval for BAFIERTAM americanpharmaceuticalreview
January 03, 2019
Banner Life Sciences announced the U.S. Food and Drug Administration (FDA) granted tentative approval on November 16, 2018 of the company’s New Drug Application (NDA 505(b)(2)) for BAFIERTAM......
Alkermes and Biogen announce new MS drug application for FDA pharmatimes
December 19, 2018
Alkermes and Biogen have announced that Alkermes has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for diroximel fumarate.
Novartis Announces EU Approval of Gilenya americanpharmaceuticalreview
November 30, 2018
Novartis announced the European Commission (EC) has approved Gilenya (fingolimod) for the treatment of children and adolescents 10 to 17 years old with relapsing-remitting forms
Novartis' Gilenya scores paediatric EU approval for advanced relapsing-remitting MS pharmafile
November 30, 2018
Novartis has announced that Gilenya (fingolimod) has received marketing authorisation from the European Commission for the treatment of relapsing-remitting forms of multiple sclerosis (RRMS) in patients aged between 10 and 17 years old...